- Inogen, Inc. (INGN, Financial) launches Voxi 5, a stationary oxygen concentrator, enhancing access to long-term oxygen therapy.
- The product combines affordability with durability, offering 1-5 L/min of continuous flow oxygen.
- Voxi 5, developed with Yuwell Medical, complements Inogen's existing portable oxygen concentrators, expanding market potential.
Inogen, Inc. (INGN), a prominent medical technology company specializing in respiratory products, has announced the launch of Voxi 5, a new stationary oxygen concentrator. This development aims to improve access to high-quality oxygen therapy for long-term care patients in the United States.
The Voxi 5, developed in collaboration with Yuwell Medical, delivers 1-5 liters per minute of continuous flow oxygen in a compact and efficient design. This innovation sets a new benchmark for affordability and durability in oxygen therapy, featuring quiet operation and equipped with caster wheels for easy mobility between rooms. Notably, the device includes an advanced filtration system for delivering medical-grade oxygen and a 3-year sieve bed warranty, promising reliable, long-term performance.
Kevin Smith, Inogen's President and CEO, emphasized the company's mission to enhance the accessibility of respiratory care. "This launch exemplifies our commitment to innovation, affordability, and enhancing the quality of life for those dependent on oxygen therapy," Smith stated.
The Voxi 5 supports Inogen's existing At Home® product lineup by offering a value-driven solution for customers sensitive to price or those needing an additional unit for multi-room use. Available through Inogen's website and authorized partners, the Voxi 5 underscores Inogen's role as a pioneer in the home oxygen therapy market, providing reliable solutions for managing chronic respiratory conditions.
